Company Overview and News
After the February correction in the stock market, Visa Inc (NYSE:V) stock rebounded sharply and threatened twice to set a new high. That’s a statement from a quality stock that deserves a second look. And therein lies my bullish opportunity today.
Thursday was a down day for the broad U.S. markets, although there have been worse. Crude oil backed off slightly during the session but it is still within striking distance from $70. The S&P 500 sectors were mostly negative. The most positive sectors were financials and energy up 1.5% and 0.2%, respectively. The worst performing sectors were consumer staples and real estate which were down 2.8% and 1.
American Express Company (NYSE:AXP) has turned heads over the past two years as the company came back from crushing lows in 2016. The credit card firm lost two of its major partnership deals that year, which halved AXP stock’s value and left many wondering if the firm was on its way out. Just this morning, American Express stock is back over $100 per share and trading at all-time highs — proof that management’s turnaround efforts have been successful.
The financial sector rose on Thursday, bucking the negative tone of the overall market and gaining as the top-performing sector of the day. The group rose 0.8%. Among the biggest gainers were American Express Co. , which surged 5.9% a day after reporting results that topped analyst forecasts. Bank of New York Mellon Corp. rose 3.6% after its own results. The gains for the broader financial sector come as the 10-year Treasury note yield rose above 2.
American Express Co. (NYSE: AXP) released first quarter financial results after markets closed Wednesday. The company reported $1.86 in earnings per share (EPS) on $9.72 billion in revenue versus consensus estimates that called for $1.71 in EPS on $9.14 billion in revenue. The same period from last year had $1.35 in EPS on $7.89 billion in revenue.
American Express Co. (NYSE: AXP) is scheduled to release its most recent quarterly results after the markets close on Wednesday. The consensus estimates from Thomson Reuters are $1.71 in earnings per share (EPS) on $9.05 billion in revenue. The same period of last year reportedly had EPS of $1.34 and $7.89 billion in revenue.
One of the best-performing large-cap stocks of the last decade, Visa Inc (NYSE:V) has struggled a bit of late. The Visa stock price still is up almost 6% YTD, but over the last two months trading in Visa has been choppy.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET